Zhitong Finance App News, Maike Pharmaceutical-B (02335.HK) announced that the phase II clinical trial of MT200605, a drug candidate developed independently by the Group to treat acute ischemic stroke, has been completed. The clinical trial has proven to have significant and robust efficacy advantages and good safety.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Maike Pharmaceutical-B (02335.HK) announced that the phase II clinical trial of MT200605, a drug candidate developed independently by the Group to treat acute ischemic stroke, has been completed. The clinical trial has proven to have significant and robust efficacy advantages and good safety.